Indevus Pharmaceuticals (NasdaqNM:IDEV) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indevus Pharmaceuticals (NasdaqNM:IDEV)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: idos	8/17/2007 8:45:53 AM
	of 78

Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy biz.yahoo.com Friday August 17, 8:00 am ET LEXINGTON, Mass., Aug. 17 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV - News) today announced that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) for VALSTAR®. VALSTAR, a sterile solution of valrubicin for intravesical instillation, is the only product approved by the FDA for therapy of bacillus Calmette-Guerin (BCG)-refractory carcinoma in situ (CIS) of the urinary bladder. VALSTAR was removed from the market in 2002 due to impurities in the original formulation and was placed on the FDA Drug Shortages List. Indevus solved the impurity issue and submitted a chemistry, manufacturing and controls (CMC) NDA supplement to the FDA in May 2007. The FDA approvable letter was in response to this chemistry supplement. In the approvable letter, the FDA asked for clarification regarding manufacturing validation protocols and for additional data on the manufacturing process. "VALSTAR offers an effective alternative for bladder cancer patients who have failed BCG therapy and are not candidates for immediate cystectomy," stated Glenn L. Cooper, M.D., chairman and chief executive officer of Indevus. "The FDA requests in the approvable letter are easily addressable with existing data and the completion of a few brief process related investigations. We expect to supply the FDA with a complete response within the next two months. We remain on track for a late 2007 or early 2008 re- introduction." About VALSTAR® snip

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next